tbuckley/cabot-search huggingface dataset:
Reply
Authors: Yeon Seok Seo, Chang Ho Jung, Tae Hyung Kim, Sun Young Yim, Soon Ho Um
Journal: Hepatology (2014)

Potential conflict of interest: Nothing to report. We sincerely appreciate the questions raised by Dr. G.‐H. Lo regarding our article.1 He questioned the effectiveness of vasoactive drugs because of the relatively high active bleeding rate and relatively low treatment success rate in our study. To be brief, the main reasons for the discrepancies would be different inclusion criteria and different definition of treatment success. The most important difference in the inclusion criteria was that we included patients with clinically significant bleeding only. Therefore, patients with more serious conditions were included, and this led to a higher active bleeding rate and a lower treatment success rate in our study. This is supported by different vital signs at baseline of our study compared to previous studies.2 In addition, some studies excluded patients with failure in hemostasis and those who died within 12 hours.4 These criteria must have excluded patients with severe bleeding or poor treatment response which led to reduced active bleeding rate in the study.4 In addition, all studies presented by Dr. Lo included patients with bleeding from esophageal varices (EVs) only, while we enrolled patients with bleeding from EVs and gastric varices, as well as EVs and those in whom endoscopy was not feasible as long as the variceal bleeding was suspected and met the inclusion criteria. Treatment success rate in patients with bleeding from EVs was 90.2% in our study, which was not significantly different from previous studies, even though patients with clinically significant bleeding only were enrolled in our study. Furthermore, in some studies, rebleeding was not included in the definition of treatment failure.5 In their study, the success rate was 97% because bleeding was controlled in 36 of 37 patients. However, because six patients rebled and if the rebleeding was defined as treatment failure as in our study, their treatment success rate would be 81.1% (30 of 37), which was lower than ours. Therefore, we conclude that a simple comparison of success rates or hemostasis rates without considering the differences in study protocols is not meaningful.
Mechanism by Which the Spleen May Act in Regulating Tumor Immunity After Tumor Resection&lt;xref ref-type="fn" rid="FN2"&gt;2&lt;/xref&gt;
Authors: R. K. Gershon, K. Kondo
Journal: JNCI Journal of the National Cancer Institute (1969)

Previous investigations showed that hamsters with intact spleens maintained a higher level of effective cell-mediated immunity, after resection of an allotransplantable lymphoma, than animals splenectomized before tumor inoculation. This was unexpected, since before the tumor graft was removed the situation was reversed and animals with intact spleens were less immune. Experiments were designed to show whether the splenic influence responsible for this increased immunity after tumor resection was exerted before or after the tumor graft was removed. Comparison was made of levels of immunity in hamsters splenectomized before tumor inoculation and animals splenectomized 7 days after inoculation, the day of tumor resection. The results showed that splenectomy at 7 days had no demonstrable effect on the subsequent immune response, and it was concluded that the splenic influence responsible for the greater immunity after tumor resection was exerted before removal of the graft. It was also shown that tumor excision led to a pronounced increase in enhancing antibody-making cells present in peritoneal exudates raised 2–5 days after tumor excision. It is suggested that the spleen produces enhancing antibodies during the first 7 days after tumor inoculation that, by some feedback mechanism, make the antibody-producing system less responsive to the stimulus to it provided by removal of the tumor graft.
Chlordiazepoxide and Hostility in Anxious Outpatients
Authors: Karl Rickels, Robert W. Downing
Journal: American Journal of Psychiatry (1974)

Chlordiazepoxide proved significantly better than placebo in reducing hostile, irritable, and anxious symptomatology in 225 anxious neurotic outpatients. The findings reported here failed to confirm the increases in hostility believed to be induced by chlordiazepoxide observed by others. The authors see little justification for avoiding use of chlordiazepoxide by anxious outpatients with concomitant hostility and irritability.
Utility of 99mTc RBC Scintigraphy in Diagnosing Parotid Venous Malformations
Authors: Rosan Patel, Hannan Saad, Ashok Srinivasan, Richard K.J. Brown
Journal: Clinical Nuclear Medicine (2015)

Venous malformations of the parotid glands are uncommon and can be difficult to confirm on routine anatomical imaging alone because of overlap of imaging features with other more common parotid lesions. 99mTc RBC scans combined with SPECT/CT offer a noninvasive way to diagnose parotid venous malformations without the need for biopsy. Combined with anatomical findings of phleboliths (when present), the diagnosis can be reliably determined. We present a case where MRI and biopsy were inconclusive, but the SPECT/CT was used to confirm the suspicion of a benign venous malformation.
Chlamydia Psittaci-Eradicating Antibiotic Therapy as a Potential Therapeutic Strategy Against Marginal Zone B-Cell Lymphoma of the Ocular Adnexa.
Authors: Andres J. Ferreri, Maurilio Ponzoni, Massimo Guidoboni, Antonia A. Lettini, Laura Caggiari, Carlo De Conciliis, Antonio Giordano Resti, Benedetta Mazzi, Rosalba Stefano, Mauro Boiocchi, Claudio Doglioni, Eugenio Villa, Riccardo Dolcetti
Journal: Blood (2004)
Conference and Workshop on Cancer Epidemiology in Latin America. Opportunities for Collaborative Research
Authors: Donald E. Henson, M.D.
Journal: JNCI Journal of the National Cancer Institute (1983)

Conference and Workshop on Cancer Epidemiology in Latin America. Opportunities for Collaborative Research Donald E. Henson, M.D. Donald E. Henson, M.D. Organ Systems Program Branch Division of Resources, Centers, and Community Activities National Cancer Institute National Institutes of Health Public Health Service U.S. Department of Health and Human Services Bethesda, Maryland 20205 Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 70, Issue 5, May 1983, Pages 979–985, https://doi.org/10.1093/jnci/70.5.979 Published: 01 May 1983
European Perspectives
Authors: Angela Maas
Journal: Circulation (2007)

D r Angela Maas' opening remarks relate immediately to of one of her recurring pressures."You are always worried about the radiation damage.I wore 3 skirts to protect my baby.I had a Geiger counter under my skirt to count the radiation.The pressure to be equal to the men and keep working during my pregnancy was immense," she says.This situation occurred during her first job, a temporary one at a hospital in Arnhem, the Netherlands, when she went through 2 pregnancies."I spent my pregnancies in the cath lab.I did more caths than some of the other cardiologists.In the first pregnancy, I was working there until 1 week before delivery.I wanted to be strong, I wanted to show that I was worth working with.When I think back, I'm amazed that none of my colleagues told me to stop.They didn't care."After her first child, she skipped her holidays and returned after 2 months.With the second pregnancy, Dr Mass says, "I didn't tell them until I was at 6½ months because I didn't want to bother them again."One male cardiologist with 4 children responded that 1 child probably was enough for her.Looking back, she says she would not do the same again."You do feel uncomfortable with a big stomach per-forming a heart cath," she says."And you don't feel comfortable, because you are worried about the baby."She had worked hard because she wanted to join the group, but after almost 5 years, she was replaced by 2 men.Perhaps her drive stems from the fact that, from the age of 4, she wanted to be a doctor.Her father had worked as a primary care physician and had a practice at home."I always wanted to make him tea, so I could have a look around and see what the patients looked like.I was always interested in what he was doing there."Dr Maas started studying medicine at Groningen University, the Netherlands, in 1974, and she spent her last 2 years of training at the St Elisabeth Hospital in Curacao, in the Caribbean-an option for all the medical students."What I liked about that was to be away and to have a lot of practical experience, because you can do a lot more there.Here, you are at the back of the queue of doctors.There, I was almost in front of the line."In Curacao, she met doctors who planned to practise as cardiologists, and that clinched her career choice."I liked the atmosphere; I liked the type of people who were becoming cardiologists.They were all men.I wanted to be like them."Their "no nonsense" approach appealed to her.She Dr Angela Maas, who works at the cardiology department of Isala Klinieken,
Adverse Effects of Proton Pump Inhibitors in Chronic Kidney Disease
Authors: Roberto Lozano
Journal: JAMA Internal Medicine (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
THU0627-HPR Exercise Therapy in Patients with Knee Osteoarthritis and Severe Pain is Enabled by Optimization of Analgesics – a Feasibility Study
Authors: J.A.C. van Tunen, M. van der Leeden, W. Bos, J. Cheung, M. van der Esch, M. Gerritsen, W.F. Peter, L.D. Roorda, G.J. Tijhuis, R. Voorneman, W.F. Lems, J. Dekker
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> Severe pain in patients with knee OA hampers the ability to exercise. A protocol for the optimization of analgesics in combination with exercise therapy was developed. The purpose of this protocol is to reduce pain and thereby allowing the patient to participate in exercise therapy. <h3>Objectives</h3> The objective of the present study was to evaluate the feasibility and outcome of the protocol. <h3>Methods</h3> Forty-nine patients with knee OA and severe knee pain (NRS-pain≥7, range 0-10) were included in this study. Analgesics were prescribed following an incremental protocol. The incremental steps were (1) acetaminophen, (2) NSAIDs, (3) weak opioids and (4) intra-articular steroid injections. After six weeks of analgesic use a supervised exercise therapy program for 12 weeks was added, consisting of muscle strengthening exercises and training of daily activities. Knee pain was assessed with NRS-pain and activity limitations were assessed with WOMAC-PF. Data were collected at baseline, after six weeks, and after 18 weeks. <h3>Results</h3> In intention-to-treat analyses statistically significant improvements in pain and activity limitations were found after six weeks of analgesic use and after the complete intervention. Mean improvements from baseline were 30% (p&lt;0.001) for pain and 16% (p&lt;0.001) for activity limitations after the complete intervention. Eighty-two percent of the patients were able to exercise according to the protocol. In these patients exercise therapy following on six weeks of analgesic use resulted in a further improvement of activity limitations of 10% (p=0.004). <h3>Conclusions</h3> The combined intervention of analgesics and exercise therapy allows most patients with knee osteoarthritis and severe pain to participate in exercise therapy, leading to reduction of pain and activity limitations. These promising results need to be confirmed in a randomized controlled trial. <h3>Disclosure of Interest</h3> None declared
THU0559 Behcet's Disease Complicated with Cerebral Venous Sinus Thrombosis: A Report of Nine Cases
Authors: L. Akyol, K. Aslan, M. Özgen, M. Sayarlıoglu
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> Behçet9s disease (BD) is a chronic and multisystemic inflammatory disorder which can affect the central nervous system. Cerebral venous sinus thrombosis (CVT) is a frequent neurological manifestation of BD. <h3>Objectives</h3> In this study, we aimed at investigating the epidemiologic, clinical, laboratory and management characteristics of our Behcet9s patients with CVT. <h3>Methods</h3> Medical records of patients with BD at department of rheumatology of the Ondokuz Mayıs university hospital from 2013 to 2015 were reviewed to identify CVT. Among 173 patients with BD, nine patients (one female and eight male) of angiographically proven CVT were identified from the records. Clinical, laboratory and management characteristics of the patients were recorded according to pre-defined protocol. <h3>Results</h3> CVT was observed in 5% (9/173) of our patients. The mean age at diagnosis was 26 (19-39) years, the mean age at onset of disease was 25 (18-39) years and the average duration of disease was 40 (3-216) months. The most common clinical presentations were headache in 7 (77%) of cases. Eight patients (89%) were affected superior sagittal sinus and transvers sinus, two patients (22.9%) were affected sigmoid sinus and cavernous sinus. Genital ulcer was found in 77% (7/9), ocular involvement in 22% (2/9), superficial thrombophlebitis in 11% (1/9) of cases. There were not found erythema nodosum and arthritis. Four patients (44%) had pulmonary thromboembolism, three patients (33%) had vena cava thrombosis, two patients (22%) had femoral and iliac vein thrombosis, one patient (11%) had cardiac thrombosis and jugular vein thrombosis, and one patient (11%) had pulmonary artery aneurysm. Erythrocyte sedimentation rate and C-reactive protein were high in all patients on admission. All patients received with corticosteroids and 8 patients received with anticoagulation therapy except one patient with pulmonary artery aneurysm. The 7 patients receiving cyclophosphamide bolus, one patient receiving anti-TNF therapy, and one patient refused immunosuppressive treatment. The patients with treated corticosteroid, immunosuppressant (cyclophosphamide or anti-TNF therapy) and/or anticoagulation treatment evolved positively with clinical improvement and good tolerance. <h3>Conclusions</h3> CVT in patients with BD may result in serious neurologic outcomes. The most common clinical presentations were headache. CVT in BD patients is male predominance, mainly multiple and venous thrombosis is more common in other site. Corticosteroid, immunosuppressant and/or anticoagulation treatment represent effective therapy. <h3>Disclosure of Interest</h3> None declared
PTU-143 Authentication and characterisation of a new oesophageal adenocarcinoma cell line: mfd-1
Authors: E Garcia, A Hayden, A Cowie, M Mellone, M Derouet, P Duriez, F Noble, MJ White, J Primrose, G Thomas, R Fitzgerald, TJ Underwood
Journal: Gut (2015)

<h3>Introduction</h3> The United Kingdom has the highest age-standardised incidence of oesophageal adenocarcinoma (EAC) in the world. EAC has a narrow window for medical intervention and 2/3 of patients present with incurable disease. Even after potentially curative surgery survival rates are at best 50% at 5 years. The oesophageal International Cancer Genome Consortium (ICGC) is elucidating the genetic landscape of oesophageal adenocarcinoma but the impact of this initiative will only be fully tangible when suitable preclinical models to validate its results become available. We describe the generation and authentication of a novel EAC cell line in a tumour from a 55-year-old male (pT4N3M0) who died from disease recurrence 7 months after neo-adjuvant chemotherapy and oesophagectomy. <h3>Method</h3> The MFD-1 cell line was expanded directly from a resected EAC specimen without any recombinant-DNA transformation. Somatic genetic variations (SGV) in DNA from MFD-1, tumour, normal oesophagus, and leucocytes were analysed genome wide with the SNP6 DNA microarray (Affymetrix). WGS was performed in tumour and leucocyte DNA (Illumina). Functional studies of MFD-1 were performed <i>in vitro</i>(3D culture + immunohistochemistry (IHC) + flow cytometry) and <i>in vivo</i>(SCID mouse xenograft). <h3>Results</h3> MFD-1 showed 98% concordance with matched tumour on genome wide SNP6 analysis. MFD-1 and the source tumour shared identical SGVs in established cancer promoting genes in EAC including deletions of SMAD4 and p16. A genetic rearrangement in the TP53 gene was observed, consistent with a copy neutral SGV with loss of heterozygosity and a duplication of a mutant TP53 allele, the Arginine 273 Histidine mutation, found in the tumour and the MFD-1 cell line. A second somatic acquired mutation was found in the new EAC candidate DOCK2 gene in the tumour, whilst amplification of a wild type allele was documented in the cell line. In 3D culture, MFD-1 was invasive and proliferative. MFD-1 is Ep-CAM positive (on flow cytometry), and in IHC stains strongly for pan-Cytokeratin and moderately for CK 7, confirming its glandular epithelial phenotype. MFD-1 formed tumours in SCID mice that developed more rapidly than the historical EAC cell lines OE33 and Flo-1. <h3>Conclusion</h3> A new tool for the <i>in vitro</i>modelling of EAC has been validated using massive parallel genotyping and sequencing of parent and cell line genomes. A genetic mechanism of malignant transformation operating in the tumour/cell line is consistent with a duplication of a mutant allele in the TP53 gene with a loss of the wild-type allele which translates as a copy neutral SGV with loss of heterozygosity. <h3>Disclosure of interest</h3> None Declared.
Outbreak of haemolytic uraemic syndrome and bloody diarrhoea due to Escherichia coli O104:H4, south-west France, June 2011
Authors: G Gault, F  X Weill, P Mariani-Kurkdjian, N Jourdan-da Silva, L King, B Aldabe, M Charron, N Ong, C Castor, M Macé, E Bingen, H Noël, V Vaillant, A Bone, B Vendrely, Y Delmas, C Combe, R Bercion, E d'Andigné, M Desjardin, P Rolland, H de Valk
Journal: Eurosurveillance (2011)

Binary file ES_Abstracts_Final_ECDC.txt matches
Colonoscopy and Multidetector-Array Computed-Tomographic Colonography: Detection Rates and Feasibility
Authors: B. Ginnerup Pedersen, T. Christiansen, N. Bjerregaard, K. Ljungmann, S. Laurberg
Journal: Endoscopy (2003)

Background and Study Aims: Computed-tomographic (CT) colonography has been introduced as a minimally invasive colon examination for the detection of colorectal neoplasms. The aim of this study was to compare the performance characteristics of multidetector-array CT colonography (MDCTC) and conventional colonoscopy in a prospective, blinded design. Patients and Methods: Sixty-six symptomatic patients, 75 patients undergoing polyp and cancer surveillance, and seven patients undergoing preoperative colonoscopy due to colorectal cancer (CRC) were examined with MDCTC and subsequent colonoscopy. The gold standard was colonoscopy. If MDCTC was positive and the first-pass colonoscopy was negative, a second-pass colonoscopy served as the gold standard. Results: Complete colonoscopy was achieved in 91 % of the patients, while technically satisfying MDCTC was obtained in 76 % of the patients (P < 0.01), insufficient air distension in the sigmoid colon being the main problem. MDCTC and colonoscopy both detected all 11 carcinomas. Overall detection rates for polypoid lesions 6 mm or larger in size were 81 % (95 % CI, 70 % to 90 %) for MDCTC and 87 % (95 % CI, 77 % to 94 %) for colonoscopy (P = 0.52), with a significant difference with regard to the detection of polyps 6 - 9 mm in size in favor of colonoscopy (P = 0.008). The specificity of MDCTC at a 6-mm level was 97 % (95 % CI, 92 % to 99 %). Conclusions: MDCTC and colonoscopy show equal overall sensitivity for the detection of polypoid lesions 6 mm or larger in size, but more patients are inadequately examined when MDCTC is used.
SAT0077 Ultrasonography as a Potent Tool for Predicting Radiographic Progression in Rheumatoid Arthritis Treated with Biological Agents
Authors: K. Mamoto, K. Inui, T. Okano, Y. Sugioka, M. Tada, T. Koike, H. Nakamura
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Objectives</h3> The aim of this study was to check whether synovial power Doppler (PD) and gray-scale (GS) ultrasound (US) scores could predict radiographic progression better than conventional measures in rheumatoid arthritis (RA) patients receiving biological agents (Bio). <h3>Methods</h3> Participants comprised 127 patients with RA who had recently received Bio. Patients underwent clinical and laboratory assessments every 2 months from baseline to 12 months, and US assessments at baseline and 6 and 12 months. GS and PD signals were scored using a semi-quantitative scale from 0 to 3 at 26 synovial sites (22 joints) in the following joints: bilateral first to fifth metacarpopharangeal (MCP) joints (dorsal recess); first interphalangeal (IP) and second to fifth proximal interphalangeal (PIP) (dorsal recess) joints; and the wrists (dorsal radial, median and ulnar). Radiographic damage to the hands and feet was evaluated using van der Heijde modified total Sharp score (TSS) at baseline and 12 months. <h3>Results</h3> Eighty-one patients finished a 12-month observation period. Univariate analysis revealed ΔTSS was significantly correlated with total GS scores at baseline (γ=0.318, P&lt;0.05), and total PD scores at baseline (γ=0.262, P&lt;0.05) and 6 months (γ=0.308, P&lt;0.05). Furthermore, after adjusting for risk factors for joint destruction, including age, sex, duration of disease and previous Bio treatments, multivariate analysis also revealed that ΔTSS correlated significantly with total GS scores at baseline (β=0.342, P&lt;0.05), and total PD scores at baseline (β=0.275, P&lt;0.05) and 6 months (β=0.336, P&lt;0.05). However, Disease Activity Score 28–CRP (DAS) did not correlate with ΔTSS. <h3>Conclusions</h3> Our data confirm the evidence that synovial PD activity more accurately reflects active synovial inflammation (which actually causes joint destruction) than conventional measures in RA patients treated using Bio. As a predictor of radiographic damage, US assessment is superior to DAS. <h3>Disclosure of Interest</h3> K. Mamoto: None declared, K. Inui: None declared, T. Okano: None declared, Y. Sugioka: None declared, M. Tada: None declared, T. Koike Grant/research support from: Takeda Pharmaceutical, Mitsubishi Tanabe Pharma Corporation, Chugai Pharmaceutical, Eisai, Abbott Japan, Teijin Pharma, Banyu Pharmaceutical and Ono Pharmaceutical, H. Nakamura: None declared